Sodium dichloroacetate

Sodium dichloroacetate is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor. Sodium dichloroacetate also stimulates pyruvate dehydrogenase (PDH) activity and works as a Na+-K+-2Cl− cotransporter (NKCC) inhibitor. Sodium dichloroacetate prevents the phosphorylation of the E1α subunit of PDC, promoting the entry of pyruvate into the mitochondria for oxidative metabolism, reducing lactate production, and simultaneously increasing the production of reactive oxygen species (ROS) . Sodium dichloroacetate inhibits tumor cell proliferation and induces apoptosis. Sodium dichloroacetate is promising for research of cancers[1][2].

Product Specifications

CAS Number

[2156-56-1]

UNSPSC

12352211

Hazard Statement

H315, H319, H335, H351

Target

Apoptosis; NKCC; PDHK; PDK-1; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sodium-dichloroacetate.html

Purity

99.78

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

O=C(O[Na])C(Cl)Cl

Molecular Formula

C2HCl2NaO2

Molecular Weight

150.92

Precautions

H315, H319, H335, H351

References & Citations

[1]Stakišaitis D, et al. The Importance of Gender-Related Anticancer Research on Mitochondrial Regulator Sodium Dichloroacetate in Preclinical Studies In Vivo. Cancers (Basel) . 2019 Aug 20;11 (8) . pii: E1210.|[2]Hossain M, et al. Cytotoxic derivatives of dichloroacetic acid and some metal complexes. Arch Pharm (Weinheim) . 2022 Nov;355 (11) :e2200236.